PATENT COOPERATION THE TYPE 15 APR 2005

From the INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY

10/531462 PCT

To:

MARCHI, Massimo Marchi & Partners S.r.l. Via Pirelli, 19 I-20124 Milano ITALIE

NOTIFICATION OF TRANSMITTAL OF THE INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Rule 71.1)

سسر

Date of mailing (day/month/year)

11.06.2004

Applicant's or agent's file reference

MM/03146/PCT

International filing date (day/month/year)

Priority date (day/month/year)

International application No. PCT/EP 03/12071

28.10.2003

29.10.2002

IMPORTANT NOTIFICATION

Applicant

ZAMBON GROUP S.P.A.

- 1. The applicant is hereby notified that this International Preliminary Examining Authority transmits herewith the international preliminary examination report and its annexes, if any, established on the international application.
- 2. A copy of the report and its annexes, if any, is being transmitted to the International Bureau for communication to all the elected Offices.
- 3. Where required by any of the elected Offices, the International Bureau will prepare an English translation of the report (but not of any annexes) and will transmit such translation to those Offices.

### 4. REMINDER

The applicant must enter the national phase before each elected Office by performing certain acts (filing translations and paying national fees) within 30 months from the priority date (or later in some Offices) (Article 39(1)) (see also the reminder sent by the International Bureau with Form PCT/IB/301).

Where a translation of the international application must be furnished to an elected Office, that translation must contain a translation of any annexes to the international preliminary examination report. It is the applicant's responsibility to prepare and furnish such translation directly to each elected Office concerned.

For further details on the applicable time limits and requirements of the elected Offices, see Volume II of the PCT Applicant's Guide.

The applicant's attention is drawn to Article 33(5), which provides that the criteria of novelty, inventive step and industrial applicability described in Article 33(2) to (4) merely serve the purposes of international preliminary examination and that "any Contracting State may apply additional or different criteria for the purposes of deciding whether, in that State, the claimed inventions is patentable or not" (see also Article 27(5)). Such additional criteria may relate, for example, to exemptions from patentability, requirements for enabling disclosure, clarity and support for the claims.

Name and mailing address of the international preliminary examining authority:



European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465 **Authorized Officer** 

Siefert, A

Tel. +49 89 2399-2469





# INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

1		or ag	ent's file reference	FOR FURTHER ACTION	See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)
1		al app 03/12	lication No. 2071	International filing date (day/mo 28.10.2003	nth/year) Priority date (day/month/year) 29.10.2002
1			ent Classification (IPC) or 007H17/00	both national classification and IPC	
Appli ZAN		N GR	OUP S.P.A.	·	
1.				amination report has been prepare applicant according to Article	ared by this International Preliminary Examining 36.
2.	This	REP	ORT consists of a total	of 4 sheets, including this cover	r sheet.
	☐ The:	bee (see	n amended and are the	e basis for this report and/or she on 607 of the Administrative Inst	of the description, claims and/or drawings which have ets containing rectifications made before this Authority ructions under the PCT).
			Mr		
3.	This	repoi	t contains indications r	elating to the following items:	
	ı	×	Basis of the opinion		
	П		Priority	·	
	Ш		Non-establishment of	opinion with regard to novelty,	nventive step and industrial applicability
	IV		Lack of unity of inven	tion	
	٧	$\boxtimes$		under Rule 66.2(a)(ii) with regations supporting such statement	d to novelty, inventive step or industrial applicability;
	VI		Certain documents ci	ted	
	VII		Certain defects in the	international application	
	VIII		Certain observations	on the international application	·
				•	
Date o	of sub	missio	n of the demand	Date o	completion of this report
06.0	5.200	04		11.06	.2004
		exami	address of the internation	nal Author	zed Officer
<del></del>	li.	D-8	opean Patent Office 0298 Munich	Bardi	i.W
		Tel. Fax	. +49 89 2399 - 0 Tx: 5236 :: +49 89 2399 - 4465	656 epmu d	one No. +49 89 2399-2132





# INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/EP 03/12071

	D : -	-4.	<u> </u>		
I.	Basis	<b>O</b> I :	tne	rei	σοπ

1. With regard to the **elements** of the international application (Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17)):

	Des	scription, Pages	
	1-4	3	as originally filed
	Cla	ima Numbara	
		ims, Numbers	-
	1-10	6	as originally filed
2.			all the elements marked above were available or furnished to this Authority in the onal application was filed, unless otherwise indicated under this item.
	The	se elements were available	or furnished to this Authority in the following language: , which is:
		the language of a translati	on furnished for the purposes of the international search (under Rule 23.1(b)).
		the language of publication	n of the international application (under Rule 48.3(b)).
		the language of a translati Rule 55.2 and/or 55.3).	on furnished for the purposes of international preliminary examination (under
3.	With inte	n regard to any <b>nucleotide</b> rnational preliminary exami	and/or amino acid sequence disclosed in the international application, the nation was carried out on the basis of the sequence listing:
		contained in the internation	nal application in written form.
		filed together with the inter	national application in computer readable form.
		furnished subsequently to	this Authority in written form.
		furnished subsequently to	this Authority in computer readable form.
		The statement that the sub in the international applica	esequently furnished written sequence listing does not go beyond the disclosure tion as filed has been furnished.
		The statement that the infolisting has been furnished.	ormation recorded in computer readable form is identical to the written sequence
4.	The	amendments have resulted	in the cancellation of:
		the description, page	St
		the claims, Nos.:	
		the drawings, sheet	s:
5.			olished as if (some of) the amendments had not been made, since they have ond the disclosure as filed (Rule 70.2(c)).
		(Any replacement sheet coreport.)	ontaining such amendments must be referred to under item 1 and annexed to this
6.	Add	itional observations, if nece	ssary:





# INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/EP 03/12071

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N) Yes: Claims 1-16

No: Claims

Inventive step (IS) Yes: Claims 1-16

No: Claims

Industrial applicability (IA) Yes: Claims 1-16

No: Claims

2. Citations and explanations

see separate sheet

## Re Item V

Reasoned statement with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

The application relates to anti-inflammatory azalide compounds devoid of antibiotic activity. The nearest prior art US-A-4 886 792 discloses azaerythronolide compounds having anti-inflammatory properties and reduced antibiotic activity (see claim 1 of the citation). These compounds lack the desosaminosyl sugar moiety which is present in the claimed compounds. The document mentions furthermore as a reference example "DESAZ" which is an azalide similar to those claimed in current claim 1. The claimed compounds differ from DESAZ in the substituents at 11-N and in modifications of their desosaminose part.

In the application the selective anti-inflammatory activity of the azalides is explained by the absence of the 3-cladinose sugar present in conventional azalide antibiotics (see page 5 of the description). Since this structural particularity is also present in "DESAZ", it appears that the pharmacological profile of "DESAZ" is similar to that of the claimed compounds.

Hence, the object of the invention can be seen in the provision of further antiinflammatory compounds as alternatives to "DESAZ". None of the available prior art documents suggests the modifications vis-à-vis the prior art disclosed in claim 1, in particular the replacement of the conventional alkyl- N-substituents by those mentioned in the claim (benzyl, (CH2)r-X-(CH2)m-Y-(CH2)n-A) or the modifications of the desosaminose when R3 is alkyl. Inventive step is therefore acknowledged.



#### From the INTERNATIONAL BUREAU

#### PCT

### NOTIFICATION CONCERNING SUBMISSION OR TRANSMITTAL OF PRIORITY DOCUMENT

(PCT Administrative Instructions, Section 411)

To:

MARCHI, Massimo Marchi & Partners S.r.I. Via Pirelli, 19 I-20124 Milano Italy

Date of mailing (day/month/year)  08 December 2003 (08.12.03)		
Applicant's or agent's file reference MM/03146/PCT	IMPORTANT NOTIFICATION	
International application No.	International filing date (day/month/year)	
PCT/EP03/12071	28 October 2003 (28.10.03)	
International publication date (day/month/year)	Priority date (day/month/year)	
Not yet published	29 October 2002 (29.10.02)	

- 1. The applicant is hereby notified of the date of receipt (except where the letters "NR" appear in the right-hand column) by the International Bureau of the priority document(s) relating to the earlier application(s) indicated below. Unless otherwise indicated by an asterisk appearing next to a date of receipt, or by the letters "NR", in the right-hand column, the priority document concerned was submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b).
- 2. This updates and replaces any previously issued notification concerning submission or transmittal of priority documents.
- 3. An asterisk(\*) appearing next to a date of receipt, in the right-hand column, denotes a priority document submitted or transmitted to the International Bureau but not in compliance with Rule 17.1(a) or (b). In such a case, the attention of the applicant is directed to Rule 17.1(c) which provides that no designated Office may disregard the priority claim concerned before giving the applicant an opportunity, upon entry into the national phase, to furnish the priority document within a time limit which is reasonable under the circumstances.
- 4. The letters "NR" appearing in the right-hand column denote a priority document which was not received by the International Bureau or which the applicant did not request the receiving Office to prepare and transmit to the International Bureau, as provided by Rule 17.1(a) or (b), respectively. In such a case, the attention of the applicant is directed to Rule 17.1(c) which provides that no designated Office may disregard the priority claim concerned before giving the applicant an opportunity, upon entry into the national phase, to furnish the priority document within a time limit which is reasonable under the circumstances.

Priority date Priority application No. Country or regional Office of priority document

29 Octo 2002 (29.10.02) MI2002A002292 IT 27 Nove 2003 (27.11.03)

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland

Authorized officer

Norbert RIGHETTO

Telephone No. (41-22) 338 9889

Facsimile No. (41-22) 338-7080